OncoMatch/Clinical Trials/NCT05861505
COLLISION RELAPSE Trial
Is NCT05861505 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B) for colorectal cancer.
Treatment: Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B) — The primary objective is to demonstrate superiority of neoadjuvant systemic therapy followed by repeat local treatment as compared to upfront repeat local treatment in patients with at least one locally treatable recurrent CRLM in the absence of extrahepatic disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: local therapy — initial CRLM
Local treatment performed for initial CRLM
Cannot have received: immunotherapy
Immuno- or chemotherapy ≤ 6 weeks prior to the randomization
Cannot have received: chemotherapy
Immuno- or chemotherapy ≤ 6 weeks prior to the randomization
Lab requirements
Blood counts
Adequate bone marrow function
Kidney function
Adequate renal function
Liver function
Adequate liver function; Compromised liver function (e.g. signs of portal hypertension, INR > 1,5 without use of anticoagulants, ascites) [excluded]
Adequate bone marrow, liver and renal function; Compromised liver function (e.g. signs of portal hypertension, INR > 1,5 without use of anticoagulants, ascites) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify